Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · IEX Real-Time Price · USD
6.95
-0.04 (-0.57%)
At close: May 2, 2024, 4:00 PM
7.24
+0.29 (4.17%)
After-hours: May 2, 2024, 7:00 PM EDT
Pasithea Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
7.33M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 15.06K | - | - |
| Dec 31, 2020 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKTTA News
- 4 days ago - Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting - GlobeNewsWire
- 9 days ago - Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers - GlobeNewsWire
- 2 months ago - Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 - GlobeNewsWire
- 4 months ago - Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position - GlobeNewsWire
- 4 months ago - Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - GlobeNewsWire
- 4 months ago - Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023 - GlobeNewsWire
- 4 months ago - Pasithea Therapeutics Announces Results from 2023 Annual Meeting - GlobeNewsWire
- 5 months ago - Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models - GlobeNewsWire